Compare AbCellera Biologics Inc (ABCL) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Wheaton Precious Metals Corp — how do they compare? AbCellera Biologics Inc trades at $9 (market cap $2.85B), while Wheaton Precious Metals Corp trades at $135.23 (market cap $60.46B). The key difference: Wheaton Precious Metals Corp is far larger — about 21.2× AbCellera Biologics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WPM | |
|---|---|---|
Market Cap | $2.85B | $60.46B |
Sector | Health | Basic Materials |
52-Week High | $9.76 | $165.72 |
52-Week Low | $2.78 | $91.02 |
Enterprise Value | $2.45B | $62.34B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Wheaton Precious Metals (WPM) trades at $134.20, up 7.1% in 24 hours, near its pivot point of $134. The stock shows strong momentum with bullish moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.19 versus $1.15 estimated, driven by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income margins exceeding 64%, while valuation ratios like P/E of 29.77 reflect premium pricing. Analysts maintain an 80% buy rating with a $161.75 consensus target.
Outlook remains positive due to robust cash flow growth and exposure to rising gold/silver prices, but risks include commodity volatility and high valuations. Institutional buying supports upside, though technical indicators suggest near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
